Immunity after COVID-19: Protection or sensitization?

Article activity feed

1. Version published to 10.1016/j.mbs.2020.108499

   Jan 1, 2021
2. 

   ScreenIT

   Jun 9, 2020

   SciScore for 10.1101/2020.05.21.20108860: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   NIH rigor criteria are not applicable to paper type.

   Table 2: Resources

   No key resources detected.

   ---

   Results from OddPub: Thank you for sharing your code.

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Of course, our model has many limitations and the real-life immune dynamics may show a more nuanced behavior in which the immunity could be lost after a certain period of time, renewed under certain levels of new exposures to the virus, or even lost again if the additional exposures are too (or too less) frequent; further investigation into the determinants of the immune dynamics is necessary to unveil the conditions of the correct and impaired …

   SciScore for 10.1101/2020.05.21.20108860: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   NIH rigor criteria are not applicable to paper type.

   Table 2: Resources

   No key resources detected.

   ---

   Results from OddPub: Thank you for sharing your code.

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Of course, our model has many limitations and the real-life immune dynamics may show a more nuanced behavior in which the immunity could be lost after a certain period of time, renewed under certain levels of new exposures to the virus, or even lost again if the additional exposures are too (or too less) frequent; further investigation into the determinants of the immune dynamics is necessary to unveil the conditions of the correct and impaired immune response. Until this is carried over, past COVID-19 patients should not be considered as having a life-time permanent acquired immunity to SARS-CoV-2 or other coronaviruses.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.05.21.20108860 on medRxiv

   May 23, 2020